Is There an Adjuvant Trial for Breast Cancer?

I think the one way I think about why such a discrepancy in, you know, what we do with tamoxifen, say, or what we would do with parpenavir in Abemma. Partly has to do with all these targeted therapies. It's great. We have them. But they also come in with a lot of toxicity. They are not benign medications that expensive. And so I think that's why the whole risk benefit kind of narrows down to the right patient until we can see that this can be justified to masses alike. That's where potentially this ease of utilizing Tamoxifen in a point five centimeter tumor versus not utilizing a parpen